Melanoma - Global Drug Forecast and Market worth 5.64 Billion USD by 2023 Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. It is estimated the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in the Mentioned in Melanoma - Global Drug Forecast and Market Analysis Report. This report, " Melanoma - Global Drug Forecast and Market Analysis to 2023" focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for melanoma. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Melanoma - Global Drug Forecast and Market Analysis Report at – http://www.absolutereports.com/pharmapoint-melanomaglobal-drug-forecast-and-market-analysis-to-2023-10076082 The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma incident cases as well as the approval and uptake of premium-priced products, such as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. Ask for Discount on Melanoma - Global Drug Forecast and Market Analysis Report at – http://www.absolutereports.com/enquiry/request-discount/10076082 The melanoma pipeline is strong; however, none of these drugs to have a major impact on the overall melanoma market, as the market is crowded with effective immunotherapies and BRAF mutationtargeted agents. The challenge for new entrants into the melanoma market is to find patient populations that are currently underserved. One of the opportunities for the companies is to work cooperatively to develop novel combinations of immuno/targeted-therapies. Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10076082 One of the main drivers of the enormous expansion of the gout market will be the launch of premiumpriced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK inhibitor combinations. +1 408 520 9750 www.absolutereports.com These drugs will extend treatment duration and replace cheaper, generic, chemotherapy regimens. - Another strong driver will be the label extension of current therapies into the new settings; for example, PD-1s will garner label extension for the first-line treatment in 2015-16, and the metastatic brands are expected to be approved in the adjuvant setting in the second half of the forecast period. About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email – [email protected] Website: www.absolutereports.com +1 408 520 9750 www.absolutereports.com